FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, specifically oncology, and can be used to assess the need for active treatment of a patient with prostate cancer (PCa). Method of the invention includes steps of obtaining a biological sample, analysing therein the category of SNP associated with PCa, (SNPpc), by determining the presence or absence of one or two risk alleles of each of the set of SNPpc, combining data related to said category of SNPpc to obtain a combined value for SNPpc, where the method, when obtaining a combined value for SNPpc, allows a subset of at least 10 % SNPpc from the category of SNPpc to be neglected, where the combined value for SNPpc is formed from data of at least 95 SNPpc, determining the correlation of said combined value for SNPpc with the likelihood of the need for active treatment for the individual. Device of the invention comprises a solid phase with a category of ligands immobilised thereon, which comprises a plurality of different ligands specifically binding to each of at least 95 SNPpc selected from SNPpc. Kit of the invention comprises an analysis device and a category of detection molecules.
EFFECT: use of inventions makes it possible to assess whether the PCa is aggressive or slowly growing and to predict the likelihood of the need for active treatment.
20 cl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR DETERMINING PRESENCE OR ABSENCE OF AGGRESSIVE PROSTATE CANCER | 2013 |
|
RU2675370C2 |
METHOD OF HARMONIZING ANALYSIS RESULTS | 2019 |
|
RU2817657C2 |
METHOD FOR DETECTING SOLID MALIGNANT TUMOR | 2015 |
|
RU2720148C2 |
METHODS FOR PREDICTING RISK OF INTERSTITIAL PNEUMONIA | 2014 |
|
RU2670148C2 |
SYSTEMS AND METHODS FOR IMPROVEMENT OF DIAGNOSTICS OF DISEASES, USING MEASURED ANALYTES | 2018 |
|
RU2782359C2 |
METHOD OF DIAGNOSING LUPUS IN HUMAN | 2010 |
|
RU2596391C2 |
MARKERS OF RISK OF CARDIOVASCULAR DISEASE | 2010 |
|
RU2524659C2 |
METHOD FOR PREDICTING THE WEIGHT OF A NEWBORN TAKING INTO ACCOUNT THE POLYMORPHIC LOCUS OF HEXOKINASE 2, DIFFERENTIALLY EXPRESSED IN THE PLACENTA | 2021 |
|
RU2786313C1 |
GENETIC MARKERS FOR PREDICTING SENSITIVITY TO THERAPY | 2014 |
|
RU2809215C2 |
GENETIC MARKERS FOR PREDICTION OF SUSCEPTIBILITY TO THERAPY | 2014 |
|
RU2707533C2 |
Authors
Dates
2018-10-16—Published
2013-11-20—Filed